Dynamics of Molecular Response in AML Patients with NPM1 and FLT3 Mutations Undergoing Allogeneic Stem Cell Transplant
Concomitant NPM1 and FLT3 mutation occurs in 20% of AML patients. Molecular response and achievement of negative minimal residual disease (MRD) are strong predictors of long-term outcome. However, little is known about the dynamics of molecular response in NPM-1 and FLT-3 double positive mutations.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Rana Salem, Radwan Massoud, Rami Mahfouz, Ali Bazarbachi, Jean El Cheikh Source Type: research
More News: Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Transplants